Repurposing the aldose reductase inhibitor and diabetic neuropathy drug epalrestat for the congenital disorder of glycosylation PMM2-CDGSangeetha Iyer, Ethan Perlstein|Disease Models & Mechanisms|2019Cited by 78
Sorbitol Is a Severity Biomarker for <scp>PMM2‐CDG</scp> with Therapeutic ImplicationsAnna N. Ligezka, Éva Morava, Mayank Saraswat et al.|Annals of Neurology|2021Cited by 57
Repurposing the aldose reductase inhibitor and diabetic neuropathy drug epalrestat for the congenital disorder of glycosylation PMM2-CDGSangeetha Iyer, Ethan Perlstein|bioRxiv (Cold Spring Harbor Laboratory)|2019Cited by 32